+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Biologics Contract Development & Manufacturing Organization Market by Service Type, Expression System, Therapeutic Category, Development Phase, End User - Global Forecast to 2030- Product Image
Biologics Contract Development & Manufacturing Organization Market by Service Type, Expression System, Therapeutic Category, Development Phase, End User - Global Forecast to 2030- Product Image
Sale

Biologics Contract Development & Manufacturing Organization Market by Service Type, Expression System, Therapeutic Category, Development Phase, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 192 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6011400
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Biologics Contract Development & Manufacturing Organization Market grew from USD 10.59 billion in 2024 to USD 11.40 billion in 2025. It is expected to continue growing at a CAGR of 7.50%, reaching USD 16.36 billion by 2030.

Shaping the Future of Biologics Development

Shaping the Future of Biologics Development

The biologics contract development and manufacturing sector is experiencing a pivotal evolution driven by scientific breakthroughs, regulatory transformations, and shifting customer priorities. Firms are compelled to adapt rapidly, embracing advanced modalities and integrated service offerings that accelerate time to market while maintaining rigorous quality standards. This introduction outlines the critical drivers of change and sets the stage for an in-depth examination of emerging market forces.

Advancements in molecular engineering and high-throughput screening have streamlined candidate selection, prompting CDMOs to expand capacity and technical capabilities. Concurrently, rising demand for personalized therapies and complex molecules has intensified competition among service providers. Regulatory authorities worldwide are harmonizing guidelines for comparability assessments and continuous manufacturing, further influencing strategic planning and capital allocation across supply chains.

Navigating Disruptive Shifts in Biologics Manufacturing

Navigating Disruptive Shifts in Biologics Manufacturing

The landscape of biologics manufacturing is undergoing transformative shifts as technological innovation converges with evolving stakeholder expectations. Continuous processing platforms are gaining traction over traditional batch production, offering improvements in consistency, scalability, and cost efficiency. Digital twins and advanced analytics are enabling real‐time monitoring that enhances process control and reduces development timelines.

Strategic partnerships between CDMOs and licensors are reshaping service models, emphasizing co-development and risk-sharing arrangements. This trend is driven by the need to manage complexity earlier in the development lifecycle, ensuring robust technology transfer and minimizing downstream disruptions. Asset light models are emerging as agile alternatives to heavy capital investment, allowing providers to tailor capacity expansions to project pipelines and market demand.

Unraveling the Impact of 2025 US Tariff Changes

Unraveling the Impact of 2025 US Tariff Changes

The introduction of new United States tariffs in 2025 has reverberated across global supply chains, affecting raw material sourcing, manufacturing costs, and pricing strategies. Heightened duties on key reagents and consumables have prompted CDMOs to reassess procurement networks, exploring alternative suppliers in regions with favorable trade agreements and localized production hubs.

These tariff adjustments have also influenced contract terms, with service providers renegotiating cost structures to mitigate margin pressures. Clients are increasingly seeking transparency in cost pass-through mechanisms and longer-term agreements that lock in pricing. In response, some CDMOs are investing in vertical integration to secure critical inputs and stabilize supply continuity, underscoring the importance of agility in tariff-impacted markets.

Unlocking Market Dynamics through Strategic Segmentation

Unlocking Market Dynamics through Strategic Segmentation

A nuanced understanding of market segments reveals critical pathways for service differentiation and revenue growth. When dissecting service type, the industry divides into drug product manufacturing and drug substance development, each requiring specialized infrastructure and regulatory acumen. Providers adept in both segments can offer seamless end-to-end solutions, capturing greater value across the development continuum.

Expression system analysis further refines competitive positioning. Mammalian platforms, including CHO, HEK, and NS0 cell lines, cater to complex glycoproteins and high-value therapeutics, while microbial systems, such as E. coli and yeast, deliver cost‐effective production for robust proteins. Recognizing these distinctions enables CDMOs to tailor capabilities to client portfolios and therapeutic targets.

Therapeutic category segmentation highlights focus areas in immunology, infectious disease, neurology, and oncology, each with unique safety profiles and regulatory pathways. Differentiation in development phase, from preclinical through Phase III and commercial manufacturing, underscores providers’ ability to scale processes and navigate varying compliance requirements. Finally, end-user segmentation spanning small to medium biotech, contract research organizations, and large pharmaceutical corporations determines the bespoke nature of service offerings and partnership frameworks.

Regional Market Nuances Driving Biologics Growth

Regional Market Nuances Driving Biologics Growth

The Americas maintain a leadership position, supported by a robust innovation ecosystem, favourable regulatory frameworks, and a deep pipeline of novel biologics. Investments in large-scale single-use facilities and advanced analytics platforms are concentrated in key hubs, driving efficiency and attracting global partnerships.

In Europe, Middle East & Africa, regulatory harmonization under initiatives like the European Medicines Agency’s adaptive pathways has streamlined approvals, encouraging service providers to expand capacity across established manufacturing centers. Strategic collaborations between local governments and industry players are bolstering infrastructure, while emerging markets within the region show growing demand for outsourcing capabilities.

Asia-Pacific demonstrates the fastest growth trajectory, fueled by government incentives, lower production costs, and a surging biotech venture capital landscape. Leading CDMOs are increasingly establishing greenfield sites and joint ventures to serve both regional clients and global customers, capitalizing on the availability of skilled talent and supportive policy frameworks.

Key Industry Players Steering Contract Manufacturing

Key Industry Players Steering Contract Manufacturing

Global leaders in biologics CDMO have differentiated through strategic capacity expansions, targeted acquisitions, and specialized technology platforms. Lonza has reinforced its mammalian manufacturing footprint with multiple flexible facilities in North America and Europe, emphasizing speed to clinic for early-stage programs. Catalent’s investment in integrated drug-product services has enabled seamless transitions from formulation to fill-finish operations, catering to large pharma and innovative biotech alike.

Samsung Biologics has quickly emerged as a powerhouse, scaling to commercial-scale operations and securing long-term partnerships through competitive pricing and rapid facility build-outs. WuXi Biologics continues to leverage its vast network in Asia-Pacific, offering end-to-end development and manufacturing solutions with cost-effective microbial and mammalian platforms. Fujifilm Diosynth Biotechnologies has carved a niche in viral vector production and gene-therapy manufacturing, aligning capabilities with the growing cell and gene therapy market.

These providers are investing in digitalization, automation, and sustainability initiatives, setting new benchmarks for quality, efficiency, and environmental stewardship. Their strategies underscore the importance of scalable, adaptable infrastructure to meet evolving project demands.

Strategic Recommendations to Lead in Biologics CDMO

Strategic Recommendations to Lead in Biologics CDMO

Industry leaders should prioritize modular facility design to accelerate capacity deployment and accommodate diverse project requirements. Embracing single-use technologies and continuous processing will drive operational flexibility and reduce capital intensity. It is imperative to cultivate strategic alliances with raw material suppliers to hedge against tariff volatility and ensure uninterrupted supply chains.

Investing in digital manufacturing platforms, including predictive process analytics and digital twins, will enhance quality oversight and expedite scale-up. Organizations must also align with regulatory authorities to pilot novel manufacturing paradigms, fostering pathways for accelerated approvals. Expanding therapeutic expertise through targeted talent acquisition and training programs will bolster service offerings in high-growth categories, including oncology and cell and gene therapies.

Finally, forging client-centric business models that blend risk-sharing, milestone-based pricing, and co-development partnerships will differentiate providers and cement long-term relationships in an increasingly competitive environment.

Rigorous Methodology Underpinning Our Insights

Rigorous Methodology Underpinning Our Insights

This analysis draws upon a comprehensive research framework that integrates both primary and secondary data sources. In-depth interviews with senior executives from leading CDMOs, biopharmaceutical sponsors, and regulatory experts provided firsthand perspectives on technological adoption, market access challenges, and strategic priorities.

Secondary research encompassed a thorough review of peer-reviewed journals, regulatory publications, corporate filings, and industry white papers. Data triangulation was employed to validate findings, ensuring consistency across varied inputs. Segmentation analysis was conducted holistically, mapping service types, expression systems, therapeutic categories, development phases, and end-user profiles to defined market dynamics.

Rigorous quality checks, including peer reviews by subject matter experts, were performed at each stage to guarantee the accuracy and relevance of the insights presented.

Concluding Perspectives on Biologics Manufacturing

Concluding Perspectives on Biologics Manufacturing

The biologics contract development and manufacturing sector stands at the intersection of innovation and operational transformation. As continuous processing, advanced analytics, and strategic partnerships redefine service models, providers that embrace agility and technological sophistication will lead the next wave of growth. Tariff dynamics and regional market nuances further underscore the need for resilient supply chains and tailored strategies.

Through disciplined segmentation and proactive engagement with emerging regulatory paradigms, CDMOs can unlock new value streams and reinforce competitive positioning. The combined influence of expression system diversification, therapeutic specialization, and development phase alignment will determine the market leaders of tomorrow. By leveraging robust data and actionable insights, stakeholders are well-positioned to navigate risks and harness the full potential of the evolving biologics landscape.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Service Type
    • Drug Product
    • Drug Substance
  • Expression System
    • Mammalian
      • Cho
      • Hek
      • Ns0
    • Microbial
      • E Coli
      • Yeast
  • Therapeutic Category
    • Immunology
    • Infectious Disease
    • Neurology
    • Oncology
  • Development Phase
    • Commercial
    • Phase I
    • Phase Ii
    • Phase Iii
    • Preclinical
  • End User
    • Biotech Small Med
    • Contract Research Org
    • Large Pharma
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Lonza Group AG
  • Catalent, Inc.
  • Samsung Biologics Co., Ltd.
  • Boehringer Ingelheim Pharma GmbH & Co. KG
  • WuXi Biologics (Cayman) Inc.
  • Thermo Fisher Scientific Inc.
  • Fujifilm Diosynth Biotechnologies U.S.A., Inc.
  • Patheon, Inc.
  • AGC Biologics Inc.
  • Merck KGaA

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Biologics Contract Development & Manufacturing Organization Market, by Service Type
8.1. Introduction
8.2. Drug Product
8.3. Drug Substance
9. Biologics Contract Development & Manufacturing Organization Market, by Expression System
9.1. Introduction
9.2. Mammalian
9.2.1. Cho
9.2.2. Hek
9.2.3. Ns0
9.3. Microbial
9.3.1. E Coli
9.3.2. Yeast
10. Biologics Contract Development & Manufacturing Organization Market, by Therapeutic Category
10.1. Introduction
10.2. Immunology
10.3. Infectious Disease
10.4. Neurology
10.5. Oncology
11. Biologics Contract Development & Manufacturing Organization Market, by Development Phase
11.1. Introduction
11.2. Commercial
11.3. Phase I
11.4. Phase Ii
11.5. Phase Iii
11.6. Preclinical
12. Biologics Contract Development & Manufacturing Organization Market, by End User
12.1. Introduction
12.2. Biotech Small Med
12.3. Contract Research Org
12.4. Large Pharma
13. Americas Biologics Contract Development & Manufacturing Organization Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Biologics Contract Development & Manufacturing Organization Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Biologics Contract Development & Manufacturing Organization Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Lonza Group AG
16.3.2. Catalent, Inc.
16.3.3. Samsung Biologics Co., Ltd.
16.3.4. Boehringer Ingelheim Pharma GmbH & Co. KG
16.3.5. WuXi Biologics (Cayman) Inc.
16.3.6. Thermo Fisher Scientific Inc.
16.3.7. Fujifilm Diosynth Biotechnologies U.S.A., Inc.
16.3.8. Patheon, Inc.
16.3.9. AGC Biologics Inc.
16.3.10. Merck KGaA
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET MULTI-CURRENCY
FIGURE 2. BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET MULTI-LANGUAGE
FIGURE 3. BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DRUG PRODUCT, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DRUG SUBSTANCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CHO, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY HEK, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY NS0, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY E COLI, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY YEAST, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOTECH SMALL MED, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT RESEARCH ORG, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE PHARMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 50. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 51. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2030 (USD MILLION)
TABLE 52. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 53. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 54. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2030 (USD MILLION)
TABLE 55. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 56. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 57. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 58. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2030 (USD MILLION)
TABLE 59. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 60. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 61. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2030 (USD MILLION)
TABLE 62. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 63. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2030 (USD MILLION)
TABLE 66. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2030 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 86. UNITED KINGDOM BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 87. UNITED KINGDOM BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2030 (USD MILLION)
TABLE 88. UNITED KINGDOM BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 89. UNITED KINGDOM BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 90. UNITED KINGDOM BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2030 (USD MILLION)
TABLE 91. UNITED KINGDOM BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 92. UNITED KINGDOM BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 93. GERMANY BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 94. GERMANY BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2030 (USD MILLION)
TABLE 95. GERMANY BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 96. GERMANY BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 97. GERMANY BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2030 (USD MILLION)
TABLE 98. GERMANY BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 99. GERMANY BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. FRANCE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 101. FRANCE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2030 (USD MILLION)
TABLE 102. FRANCE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 103. FRANCE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 104. FRANCE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2030 (USD MILLION)
TABLE 105. FRANCE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 106. FRANCE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 107. RUSSIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 108. RUSSIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2030 (USD MILLION)
TABLE 109. RUSSIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 110. RUSSIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 111. RUSSIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2030 (USD MILLION)
TABLE 112. RUSSIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 113. RUSSIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 114. ITALY BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 115. ITALY BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2030 (USD MILLION)
TABLE 116. ITALY BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 117. ITALY BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 118. ITALY BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2030 (USD MILLION)
TABLE 119. ITALY BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 120. ITALY BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 121. SPAIN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 122. SPAIN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2030 (USD MILLION)
TABLE 123. SPAIN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 124. SPAIN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 125. SPAIN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2030 (USD MILLION)
TABLE 126. SPAIN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 127. SPAIN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 128. UNITED ARAB EMIRATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 129. UNITED ARAB EMIRATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2030 (USD MILLION)
TABLE 130. UNITED ARAB EMIRATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 131. UNITED ARAB EMIRATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 132. UNITED ARAB EMIRATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2030 (USD MILLION)
TABLE 133. UNITED ARAB EMIRATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 134. UNITED ARAB EMIRATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 135. SAUDI ARABIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 136. SAUDI ARABIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2030 (USD MILLION)
TABLE 137. SAUDI ARABIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 138. SAUDI ARABIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 139. SAUDI ARABIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2030 (USD MILLION)
TABLE 140. SAUDI ARABIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 141. SAUDI ARABIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 142. SOUTH AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 143. SOUTH AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2030 (USD MILLION)
TABLE 144. SOUTH AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 145. SOUTH AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 146. SOUTH AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2030 (USD MILLION)
TABLE 147. SOUTH AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 148. SOUTH AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 149. DENMARK BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 150. DENMARK BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2030 (USD MILLION)
TABLE 151. DENMARK BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 152. DENMARK BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 153. DENMARK BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2030 (USD MILLION)
TABLE 154. DENMARK BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 155. DENMARK BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 156. NETHERLANDS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 157. NETHERLANDS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2030 (USD MILLION)
TABLE 158. NETHERLANDS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 159. NETHERLANDS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 160. NETHERLANDS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2030 (USD MILLION)
TABLE 161. NETHERLANDS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 162. NETHERLANDS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 163. QATAR BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 164. QATAR BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2030 (USD MILLION)
TABLE 165. QATAR BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 166. QATAR BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 167. QATAR BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2030 (USD MILLION)
TABLE 168. QATAR BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 169. QATAR BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 170. FINLAND BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 171. FINLAND BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2030 (USD MILLION)
TABLE 172. FINLAND BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 173. FINLAND BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 174. FINLAND BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2030 (USD MILLION)
TABLE 175. FINLAND BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 176. FINLAND BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 177. SWEDEN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 178. SWEDEN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2030 (USD MILLION)
TABLE 179. SWEDEN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 180. SWEDEN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 181. SWEDEN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2030 (USD MILLION)
TABLE 182. SWEDEN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 183. SWEDEN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 184. NIGERIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 185. NIGERIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2030 (USD MILLION)
TABLE 186. NIGERIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 187. NIGERIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 188. NIGERIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2030 (USD MILLION)
TABLE 189. NIGERIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 190. NIGERIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 191. EGYPT BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 192. EGYPT BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2030 (USD MILLION)
TABLE 193. EGYPT BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 194. EGYPT BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 195. EGYPT BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2030 (USD MILLION)
TABLE 196. EGYPT BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 197. EGYPT BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 198. TURKEY BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 199. TURKEY BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2030 (USD MILLION)
TABLE 200. TURKEY BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 201. TURKEY BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 202. TURKEY BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2030 (USD MILLION)
TABLE 203. TURKEY BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 204. TURKEY BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 205. ISRAEL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 206. ISRAEL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2030 (USD MILLION)
TABLE 207. ISRAEL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 208. ISRAEL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 209. ISRAEL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2030 (USD MILLION)
TABLE 210. ISRAEL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 211. ISRAEL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 212. NORWAY BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 213. NORWAY BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2030 (USD MILLION)
TABLE 214. NORWAY BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 215. NORWAY BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 216. NORWAY BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2030 (USD MILLION)
TABLE 217. NORWAY BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 218. NORWAY BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 219. POLAND BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 220. POLAND BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2030 (USD MILLION)
TABLE 221. POLAND BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 222. POLAND BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 223. POLAND BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2030 (USD MILLION)
TABLE 224. POLAND BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 225. POLAND BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 226. SWITZERLAND BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 227. SWITZERLAND BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2030 (USD MILLION)
TABLE 228. SWITZERLAND BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 229. SWITZERLAND BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 230. SWITZERLAND BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2030 (USD MILLION)
TABLE 231. SWITZERLAND BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 232. SWITZERLAND BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 233. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 234. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2030 (USD MILLION)
TABLE 235. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2030 (USD MILLION)
TABLE 236. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2030 (USD MILLION)
TABLE 237. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2030 (USD MILLION)
TABLE 238. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2030 (USD MILLION)
TABLE 239. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 240. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 241. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 242. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2030 (USD MILLION)
TABLE 243. CHINA BIOLOGICS CONTRA

Companies Mentioned

The companies profiled in this Biologics Contract Development & Manufacturing Organization market report include:
  • Lonza Group AG
  • Catalent, Inc.
  • Samsung Biologics Co., Ltd.
  • Boehringer Ingelheim Pharma GmbH & Co. KG
  • WuXi Biologics (Cayman) Inc.
  • Thermo Fisher Scientific Inc.
  • Fujifilm Diosynth Biotechnologies U.S.A., Inc.
  • Patheon, Inc.
  • AGC Biologics Inc.
  • Merck KGaA

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages192
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 11.4 Billion
Forecasted Market Value ( USD ) by 2030 $ 16.36 Billion
Compound Annual Growth Rate7.5%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Biologics Contract Development Market by Service Type, Molecule Type, Therapeutic Area, Host System, End User, Technology - Global Forecast to 2030 - Product Image

Biologics Contract Development Market by Service Type, Molecule Type, Therapeutic Area, Host System, End User, Technology - Global Forecast to 2030

  • Report
  • 186 Pages
  • Global
From
Biologics Contract Manufacturing Market by Molecule Type, Process Step, Production Scale, Technology Platform, Therapeutic Area, End User, Manufacturing Model - Global Forecast to 2030 - Product Image

Biologics Contract Manufacturing Market by Molecule Type, Process Step, Production Scale, Technology Platform, Therapeutic Area, End User, Manufacturing Model - Global Forecast to 2030

  • Report
  • 181 Pages
  • Global
From
Biologics Contract Manufacturing Market Size, Share & Trends Analysis Report By Product, By Indication, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Biologics Contract Manufacturing Market Size, Share & Trends Analysis Report By Product, By Indication, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 180 Pages
  • Global
From
Biopharmaceuticals Contract Manufacturing Market Size, Share, & Trend Analysis Report by Source, Service (Process Development), Drug Type (Biologics, Biosimilars), Type, Scale of Operation, Therapeutic Area, Region, and Segment Forecasts, 2025-2030 - Product Image

Biopharmaceuticals Contract Manufacturing Market Size, Share, & Trend Analysis Report by Source, Service (Process Development), Drug Type (Biologics, Biosimilars), Type, Scale of Operation, Therapeutic Area, Region, and Segment Forecasts, 2025-2030

  • Report
  • 150 Pages
  • Global
From
Biologics Contract Development - Global Strategic Business Report - Product Image

Biologics Contract Development - Global Strategic Business Report

  • Report
  • 172 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.